SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer's disease
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.14579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Dylan J Terstege und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Selective Serotonin Reuptake Inhibitors, Dorsal Raphe Nucleus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIH HHS, ADNI.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Tau pathology impacts neurodegeneration and cognitive decline in Alzheimer's disease (AD), with the dorsal raphe nucleus (DRN) being among the brain regions showing the earliest tau pathology. As a serotonergic hub, DRN activity is altered by selective serotonin reuptake inhibitors (SSRIs), which also have variable effects on cognitive decline and pathology in AD. METHODS We examined N = 191 subjects with baseline 18 F‐fluorodeoxyglucose positron emission tomography and plasma biomarker data to study the effects of SSRIs on tau pathology, cognitive decline, and DRN metabolism. RESULTS Plasma phosphorylated tau 181 (p‐tau181) was lower with SSRI use. The effect of SSRIs on cognition varied by cognitive assessment. The DRN was hypometabolic in AD patients relative to healthy controls; however, SSRI use restored the metabolic activity of this region in AD patients. DISCUSSION Long‐term SSRI use may reduce the pathological presentation of AD but has variable effects on cognitive performance. Highlights Tau pathology spreads throughout the brain during AD pathogenesis. The DRN is among the first regions to develop tau pathology during this process. SSRI use restores the metabolic activity of the DRN and reduces plasma p‐tau181.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
- Department of Psychology, University of Calgary, Calgary, Alberta, Canada.
- Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
ORCID-Profile: Dylan J Terstege, Derya Sargin
Förderung
- NIA NIH HHS
- NIH HHS
- ADNI
- NIBIB NIH HHS
- Alzheimer Society Research Program
- Women's Brain Health Initiative in partnership with Brain Canada
- National Institutes of Health
- Alzheimer's Disease Neuroimaging Initiative
Zitieren
APA
Terstege, D. J., Jabeen, S., Alzheimer's Disease Neuroimaging Initiative, Galea, L. A. M., Epp, J. R., & Sargin, D. (2025). SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14579
Vancouver
Terstege DJ, Jabeen S, Alzheimer's Disease Neuroimaging Initiative, Galea LAM, Epp JR, Sargin D. SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14579
BibTeX
@article{Terstege2025,
author = {Terstege, Dylan J and Jabeen, Shaista and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative and Galea, Liisa A M and Epp, Jonathan R and Sargin, Derya},
title = {SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.14579}
}
EUVIMED